TA-AVI Using An Investigational Self—Expandable Bioprosthesis: 30 Day Outcomes  by unknown
FEATURED CLINICAL RESEARCH
TA-AVI Using An Investigational Self—Expandable Bioprosthesis: 30 Day
Outcomes
Joerg Kempfert, Markus Schönburg, Helge Möllmann, Ardwan Rastan, David
Holzhey, Hendrik Treede, Stephan Baldus, Matthias Thielmann, Daniel Wendt,
Holger Schröfel, Martin Heimeshoff, Friedrich Mohr, Thomas Walther
Background: Transapical aortic valve implantation (TA-AVI) is a standard approach
for high-risk elderly patients using the balloon expandable Edwards SAPIEN™. As
an alternative we are evaluating the Symetis ACURATE TA™, a new self-expanding
transapical bioprosthesis, in a pilot study.
Methods: This novel device, composed of a porcine biologic valve attached to a self-
expandable nitinol stent, is unsheathed proximally towards the apex and is designed for
anatomical orientation of the commissures and subcoronary implantation using a
simple intuitive two-step deployment. The device accommodates native annular sizes
of 21mm to 27mm. An Ethics Committee approved the study and all patients provided
informed consent.
Results: Fifty (50) patients have been treated. Mean patient age is 83.7 ± 4.3 years,
76% are female and all presented with NYHA Class III/IV with a mean logistic
EuroSCORE of 19.6 ± 6.6% and STS Score of 8.4 ± 8.1%. Forty-seven (47) implants
were delivered successfully in the intra-annular and subcoronary position for a
procedural success rate of 94%. There were 2 conversions to conventional surgery and
1 valve-in-valve implantation. All implants were performed off-pump. To date, at 30
days post-implant, ECHO control reveals 1 patient with paravalvular leak of +2 and the
remainder with ≤ +1 and no incidence of relevant (≥ 1+) central leak. The mean aortic
gradient is 12.5 ± 5.0 mmHg with a mean EOA of 1.3 ± 0.4 cm2. Two patients expired
by 30 days (4% mortality rate): 1 from a nonvalve- related cause (respiratory
complication) and 1 following annular dissection and subsequent conversion to surgery.
There was 1 reported stroke and 7 new pacemaker implants by 30 days.
Conclusion: This preliminary 30 day data indicates good function and outcomes after
TA-AVI using the device in high- risk patients with aortic stenosis. Complete primary
endpoint (30 day) results from the completed study will be presented for the first time
at TCT 2011.
1 Year Outcomes of Trans-catheter Aortic Valve Implantation in the UK:
Comparison of Valve Type and Access Route
Daniel Blackman, Philip MacCarthy
Background: Registry data and recent randomized controlled trials have established
the safety and efficacy of TAVI in certain patients. An effective multidisciplinary “Heart
Team” selects patients who may benefit and tailors therapy accordingly. However, little
is yet known about differences in outcomes after this selection process – according to
valve type and access route. The UK TAVI Registry captures all procedures performed
in the UK and tracks mortality in 100% of patients, making it one of the most
comprehensive TAVI registry datasets available. We present the UK survival of patients
undergoing TAVI at 1 year according to the valve type and the access route.
Methods: 1620 consecutive patients undergoing TAVI from 1st Jan 2007-31st Dec
2010 were analysed. Procedures were performed in 32 centres (experience range n=1-
178). A comprehensive dataset was input via local databases to a central database
(UK-CCAD). Mortality tracking was performed via the NHS Central Register.
Results: Patients formed 4 groups: Trans-femoral (TF) Sapien n=389 (Edwards
Lifesciences, Irvine, US); TF CoreValve n=706 (Medtronic Inc, US); Trans-apical (TA)
Sapien n=410; and Subclavian (SC) CoreValve n=92. Patient characteristics are shown in
Table 1. Outcomes according to group are shown in Table 2. Statistical comparison is
made between the Sapien TF and CoreValve TF groups and the Sapien TA and CoreValve
SC groups because of their broad clinical similarity. Kaplan-Meier curves are shown
comparing Sapien TF vs CoreValve TF (Figure 1) and comparing access route (Figure 2).
Conclusion: These outcomes compare favourably with published series. No difference
is observed between Sapien TF and CoreValve TF at 1yr. Patient risk profile is higher
with Sapien TA/CoreValve SC and mortality is higher in these groups. 30 day mortality
is higher in the Sapien TA group than the CoreValve SC group but there is no difference
at 1 year. The reason for this observation is not clear and requires further study. The
incidence of AR>2+ and need for permanent pacing is greater with CoreValve.
Correlation between Platelet Reactivity and Type of Post-discharge Bleeding
Events in PCI-treated Patients: Results of the ACCEL-BLEED study
Young-Hoon Jeong, Tae Jung Kwon, Udaya S. Tantry, Yongwhi Park, Seok-Jae
Hwang, Kevin P. Bliden, Choong Hwan Kwak, Jin-Yong Hwang, Paul A. Gurbel
Background: The relation of platelet reactivity (PR) to bleeding events in PCI-treated
patients is unclear. Because bleeding events immediately after PCI are influenced by
multiple therapies and risk factors, we evaluated whether PR correlates with post-
discharge bleeding complications.
Methods: PCI-treated patients (n=252) without in-hospital complication were
prospectively enrolled. Platelet measures were assessed in-hospital and at 30-day
follow-up by light transmittance aggregometry (LTA) and VASP-P assay. The primary
end point was the correlation of PR and 30-day incidence of bleeding events assessed
by TIMI bleeding score or detailed BleedScore™.
Results: No patients suffered from TIMI major or minor bleeding. A total of 93 patients
experienced BleedScore™ bleeding events (29.8%), of which 21.9% were superficial,
and 7.9% were internal. Baseline demographics did not significantly differ across the
bleeding type. There were no differences in in-hospital PR depending on the bleeding
type. Compared to other patients, those with an episode of internal bleeding had
significantly lower values of 30-day PR (VASP index, 54.8±17.3% vs. 45.2±18.7%,
p=0.021; 20µM ADP-PR, 50.0±18.9% vs. 37.5±22.8%, p=0.006. By ROC curve
analysis, the optimal cutoffs for predicting internal bleeding were 20µM ADP-PR at 30-
day ≤46% (AUC 0.663, 95% CI 0.525 to 0.802, p=0.016) and VASP index at 30-day
≤45% (AUC 0.640, 95% CI 0.506 to 0.774, p=0.043). In multivariate analysis, 20µM
ADP-PR at 30-day ≤46% was associated with a 4.5-fold increased risk for internal
bleeding. VASP index at 30-day ≤45% was moderately associated with internal
bleeding (OR 2.8, 95% CI 1.0 to 8.0, p=0.051).
Conclusion: Among patients undergoing PCI, ADP-induced platelet reactivity at 30-
day is associated with risk for post- discharge internal bleeding. BleedScore™ bleeding
scale can be utilized to assess detailed safety profile in clinical trials using potent
P2Y12 inhibitors.
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